CN107952062A - Animal respiratory tract protective agents and preparation method thereof - Google Patents
Animal respiratory tract protective agents and preparation method thereof Download PDFInfo
- Publication number
- CN107952062A CN107952062A CN201711499195.9A CN201711499195A CN107952062A CN 107952062 A CN107952062 A CN 107952062A CN 201711499195 A CN201711499195 A CN 201711499195A CN 107952062 A CN107952062 A CN 107952062A
- Authority
- CN
- China
- Prior art keywords
- parts
- animal
- respiratory tract
- protective agents
- moringa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 131
- 210000002345 respiratory system Anatomy 0.000 title claims abstract description 97
- 239000003223 protective agent Substances 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 53
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 239000006041 probiotic Substances 0.000 claims abstract description 44
- 235000018291 probiotics Nutrition 0.000 claims abstract description 44
- 230000000529 probiotic effect Effects 0.000 claims abstract description 40
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 claims abstract description 32
- 229960001163 pidotimod Drugs 0.000 claims abstract description 32
- 241000220215 Moringa Species 0.000 claims abstract 10
- 239000000463 material Substances 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 31
- 229940088594 vitamin Drugs 0.000 claims description 28
- 239000011782 vitamin Substances 0.000 claims description 28
- 229920001542 oligosaccharide Polymers 0.000 claims description 27
- 150000002482 oligosaccharides Chemical class 0.000 claims description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 23
- 229920002472 Starch Polymers 0.000 claims description 23
- 239000008107 starch Substances 0.000 claims description 23
- 235000019698 starch Nutrition 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 241000168517 Haematococcus lacustris Species 0.000 claims description 18
- 239000011573 trace mineral Substances 0.000 claims description 18
- 235000013619 trace mineral Nutrition 0.000 claims description 18
- 241000193171 Clostridium butyricum Species 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 14
- 210000004185 liver Anatomy 0.000 claims description 14
- 244000063299 Bacillus subtilis Species 0.000 claims description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 13
- 239000002131 composite material Substances 0.000 claims description 13
- 235000013355 food flavoring agent Nutrition 0.000 claims description 13
- 239000002002 slurry Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 12
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 12
- 239000011719 vitamin A Substances 0.000 claims description 12
- 235000019155 vitamin A Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 229940045997 vitamin a Drugs 0.000 claims description 12
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 11
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- 239000000853 adhesive Substances 0.000 claims description 11
- 230000001070 adhesive effect Effects 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 229960002477 riboflavin Drugs 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 229960003495 thiamine Drugs 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 229930003451 Vitamin B1 Natural products 0.000 claims description 10
- 229930003471 Vitamin B2 Natural products 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 235000010413 sodium alginate Nutrition 0.000 claims description 10
- 239000000661 sodium alginate Substances 0.000 claims description 10
- 229940005550 sodium alginate Drugs 0.000 claims description 10
- 235000010374 vitamin B1 Nutrition 0.000 claims description 10
- 239000011691 vitamin B1 Substances 0.000 claims description 10
- 235000019164 vitamin B2 Nutrition 0.000 claims description 10
- 239000011716 vitamin B2 Substances 0.000 claims description 10
- 241000287828 Gallus gallus Species 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- 235000012054 meals Nutrition 0.000 claims description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- TWNIBLMWSKIRAT-RWOPYEJCSA-N (1r,2s,3s,4s,5r)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](O)[C@H](O)[C@@H]2O TWNIBLMWSKIRAT-RWOPYEJCSA-N 0.000 claims description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- -1 hydroxypropyl methyl Chemical group 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000011669 selenium Substances 0.000 claims description 8
- 229910052711 selenium Inorganic materials 0.000 claims description 8
- 239000011122 softwood Substances 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 229910052748 manganese Inorganic materials 0.000 claims description 7
- 239000011572 manganese Substances 0.000 claims description 7
- 239000012071 phase Substances 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 235000019166 vitamin D Nutrition 0.000 claims description 7
- 239000011710 vitamin D Substances 0.000 claims description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 7
- 229940046008 vitamin d Drugs 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000375 suspending agent Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 235000015278 beef Nutrition 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 235000015277 pork Nutrition 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical group OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229940049964 oleate Drugs 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 239000003182 parenteral nutrition solution Substances 0.000 claims description 3
- 238000005453 pelletization Methods 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 239000000196 tragacanth Substances 0.000 claims description 3
- 229940116362 tragacanth Drugs 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 35
- 230000003115 biocidal effect Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 12
- 208000030303 breathing problems Diseases 0.000 abstract description 9
- 208000023504 respiratory system disease Diseases 0.000 abstract description 9
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000008092 positive effect Effects 0.000 abstract description 3
- 230000000241 respiratory effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 244000179886 Moringa oleifera Species 0.000 description 43
- 238000012360 testing method Methods 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 20
- 229940032147 starch Drugs 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 15
- 230000036039 immunity Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000019629 palatability Nutrition 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 244000182067 Fraxinus ornus Species 0.000 description 2
- 235000002917 Fraxinus ornus Nutrition 0.000 description 2
- 241000168525 Haematococcus Species 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 240000005578 Rivina humilis Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000005667 attractant Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000031902 chemoattractant activity Effects 0.000 description 2
- 235000019621 digestibility Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 229940080313 sodium starch Drugs 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- VAJVDSVGBWFCLW-UHFFFAOYSA-N 3-Phenyl-1-propanol Chemical compound OCCCC1=CC=CC=C1 VAJVDSVGBWFCLW-UHFFFAOYSA-N 0.000 description 1
- VJFMSYZSFUWQPZ-BIPCEHGGSA-N 4-[(r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-hydroxymethyl]quinolin-6-ol Chemical compound C1=C(O)C=C2C([C@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 VJFMSYZSFUWQPZ-BIPCEHGGSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000195627 Chlamydomonadales Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000206751 Chrysophyceae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 1
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 241000486406 Trachea Species 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- VJFMSYZSFUWQPZ-UHFFFAOYSA-N demethyl quinine Natural products C1=C(O)C=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 VJFMSYZSFUWQPZ-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
The invention discloses a kind of animal respiratory tract protective agents and preparation method thereof, it is related to animal-use drug technical field.The animal includes Pidotimod, Moringa, epiphysin, microalgae and compound probiotic with respiratory tract protective agents；The preparation method comprises the following steps：Pidotimod, Moringa, epiphysin, microalgae, compound probiotic are uniformly mixed, that is, animal respiratory tract protective agents are made.The present invention alleviates treats animal respiratory disease mainly by antibiotic at present, treatment time is grown, in easy the problem of producing drug resistance during treatment, adjuvant drug of the medicine provided by the invention as treatment breathing problem, treatment cycle of the respiratory drugs to breathing problem can be shortened, therapeutic effect is good, and positive effect can be obtained by taking in one week, efficient up to more than 96%.
Description
Technical field
The present invention relates to animal-use drug technical field, in particular to a kind of animal with respiratory tract protective agents and its
Preparation method.
Background technology
Respiratory tract system disease is the major class in Animal diseases, and the respiratory disease of animal mainly has flu, pharyngitis
With capillary bronchitis, bronchitis etc..Flu can cause animal breath systemic disease, and with multiple complications, by more
The kind cause of disease causes rheum.The flu of animal is caused by catching cold, if the flu state of an illness cannot be timely under normal conditions
Control can cause sphagitis and pneumonia.Major part raiser lacks rational feeding manner at present, and does not have epidemic disease epidemic prevention
Knowledge, causes animal or pet respiratory tract system disease incidence higher.
The prevention of respiratory disease, it is crucial to prevent that animal from suffering from cold.Such as pet bathing when, either winter also
It it is summer, water temperature can not all be less than pet itself body temperature, and should after a bath dry up at once afterwards；Summer weather is hot, pet
It is sure not draught during sleep；Winter intemperance, should strengthen pet outdoor activities amount, build up health, and improve resistance and resist cold
Power.In addition, prevention respiratory disease, should prevent penetrating odor, environmental pollution etc. from damaging away from toxic gas, pernicious gas
The pernicious gas of evil respiratory mucosa.Lodge house will keep suitable temperature and humidity, prevent bronchitis and broncho-pulmonary
Scorching generation.
Treatment animal respiratory disease is also clinically root mainly by antibiotic, domestic most of pet clinics at present
According to going with some antibiotic for experience, if blindly going to replace antibiotic if rear effect unobvious.But with antibiotic
Since treatment time is grown when treating animal respiratory disease, infected animal may be made during treatment to certain antibiotic
Produce drug resistance.
In view of this, it is special to propose the present invention.
The content of the invention
It is an object of the present invention to providing a kind of animal respiratory drugs, controlled with alleviating existing use antibiotic
Treatment time is grown when treating animal respiratory disease, thereby increases and it is possible to can ask the technology that infected animal produces certain antibiotic drug resistance
Topic.
Animal provided by the invention respiratory tract protective agents, including Pidotimod, Moringa, epiphysin, microalgae and compound
Probiotics；
Preferably, the Moringa is Moringa extract；
Preferably, the microalgae is haematococcus pluvialis；
Preferably, the compound probiotic includes clostridium butyricum and bacillus subtilis.
Further, animal respiratory tract prevention medicine includes following component according to the mass fraction：Pidotimod 2-
20 parts, 5-30 parts of Moringa, 0.1-1 parts of epiphysin, 1-15 parts of 0.2-3 parts of microalgae and compound probiotic；
Further, animal respiratory tract protective agents, including following component according to the mass fraction：Pidotimod
5-18 parts, 8-25 parts of Moringa, 0.2-0.6 parts of epiphysin, 3-12 parts of 0.5-2 parts of microalgae and compound probiotic；
Preferably, animal respiratory tract protective agents, including following component according to the mass fraction：Pidotimod 8-
16 parts, 10-20 parts of Moringa, 0.2-0.6 parts of epiphysin, 3-12 parts of 0.5-2 parts of microalgae and compound probiotic.
Further, animal respiratory tract protective agents, further include 0.1-10 parts of multi-vitamins, are preferably 0.1-
5 parts；
Preferably, the multi-vitamins include vitamin A, vitamin C, vitamin E, vitamin B1, vitamin B2 and
At least two in D-VB5 calcium.
Further, animal respiratory tract protective agents, further include 0.1-10 parts of composite trace element, are preferably
0.1-5 parts；
Preferably, the composite trace element includes at least two in copper, zinc, selenium and manganese.
Further, animal respiratory tract protective agents, further include 2-10 parts of activated oligosaccharide, are preferably 3-7 parts；
Preferably, the activated oligosaccharide includes mannosan and/or oligoisomaltose.
Further, animal respiratory tract protective agents, further include 15-50 parts of auxiliary material, are preferably 20-40 parts.
Preferably, the auxiliary material includes adhesive, disintegrant, lubricant, flavouring agent, emulsifying agent, suspending agent, oil phase base
At least one of matter, aqueous phase substrate, solvent, flavouring agent and diluent；
Preferably, described adhesive is selected from least one of maltodextrin, sodium alginate, polyvinylpyrrolidone；
Preferably, the disintegrant is in sodium carboxymethyl starch, sodium carboxymethylcellulose, microcrystalline cellulose or starch
It is at least one；
Preferably, the lubricant is selected from least one of silica, magnesium stearate, odium stearate or talcum powder；
Preferably, the emulsifying agent is selected from lauryl sodium sulfate, stearate, oleate, spans, Tweens, pool
Luo Shamu, sucrose stearate, Brij, sell at least one of pool；
Preferably, the suspending agent is selected from methylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl first
Base cellulose, hydroxyethyl cellulose, Arabic gum, at least one of tragacanth, sodium alginate；
Preferably, the oil phase substrate is selected from least one of vegetable oil, atoleine, glycerine；
Preferably, the one kind of the aqueous phase substrate in water or ethanol solution；
Preferably, the one kind of the solvent in water, ethanol, propane diols；
Preferably, the flavouring agent is selected from least one of plants essential oil, chicken liver meal, pork liver powder or powdered beef；
Preferably, the diluent is selected from least one of lactose, glucose or mannitol.
Further, the animal is tablet, granule, paste, oral liquid, injection with the formulation of respiratory tract protective agents
Liquid, cream, patch, suspension or pulvis；
Preferably, the animal is tablet with the formulation of respiratory tract protective agents.
The second object of the present invention is to provide preparation method of the above-mentioned animal with respiratory tract protective agents, including following step
Suddenly：
By Pidotimod, Moringa, epiphysin, microalgae, optionally compound probiotic, multi-vitamins, optionally compound micro-
Secondary element, optionally activated oligosaccharide and optionally auxiliary material is uniformly mixed, that is, be made animal respiratory tract protective agents.
Further, by Pidotimod, Moringa, epiphysin, microalgae, compound probiotic, optionally multi-vitamins, optionally
Ground composite trace element, optionally activated oligosaccharide and optionally auxiliary material after mixing, add starch slurry softwood, through pelletizing,
It is dry, dry particl is obtained, after dry particl tabletting, that is, tablet form animal respiratory tract protective agents are made；
Preferably, the mass percentage of starch is 5~15% in starch slurry；
Preferably, the mass percent that starch slurry accounts for animal respiratory tract protective agents is 10~15%；
Preferably, the piece weight of tablet is 0.55-0.65g；
Preferably, tableting pressure 5-7kg.
Compared with the prior art, the present invention has the advantages that：
(1) animal provided by the invention by Pidotimod, Moringa, epiphysin, microalgae and is answered with respiratory tract protective agents
Probiotics coordinated is closed, fragrant odour, phagostimulating effect, palatability are good, can substantially mitigate animal respiratory disease symptom, improve
Animal body immunity, can arrange in pairs or groups with conventional antibiotic and use, shorten the treatment cycle to breathing problem, take in one week
Positive effect can be obtained, to the effective percentage reachable more than 96% of dog.Meanwhile animal provided by the invention prevents medicine with respiratory tract
Thing also has improvement body environment, safeguards the effect of organ health and anti-aging.
(2) animal provided by the invention is simple with the preparation method technique of respiratory tract protective agents, easy to operate, Neng Goujie
About substantial amounts of manpower and materials, can be suitable for industrialized production.
Embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will
Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the invention.It is not specified in embodiment specific
Condition person, the condition suggested according to normal condition or manufacturer carry out.Reagents or instruments used without specified manufacturer, is
The conventional products that can be obtained by commercially available purchase.
According to an aspect of the present invention, the present invention provides a kind of animal respiratory tract protective agents, including more than not
Moral, Moringa, epiphysin, microalgae and compound probiotic.
In the present invention, Pidotimod is a kind of artificial synthesized thymus gland dipeptide structure, is made of 2 amino acid, is one
Kind immunomodulator, suitable for the low patient of body's immunity, and available for acute infection is prevented, shortens the course of disease, reduces
The severity of disease, can have activation immune cell, improves immunity of organisms as the adjuvant drug of acute infection period
With the effect for eliminating immunization inflammatory reaction.
In the present invention, Moringa can be derived from Moringa oleifera in itself, such as leaf of Moringa, moringa root, Moringa flower or moringa seeds
Deng the powder directly obtained after processing, Moringa (such as leaf of Moringa, moringa root, Moringa flower or moringa seeds) can also be derived from through carrying
Moringa extract after taking.
Moringa contains abundant nutrition element, containing the necessary natural nutrient of more than 30 kinds of organisms, includes about 20 kinds of amino
Acid, 46 kinds of antioxidants, anti-inflammatory compound, rich in abundant trace element and arginine, lysine, leucine, phenylpropyl alcohol ammonia
Acid etc., there is provided vitamin A, vitamin B complex, vitamin C, vitamin E and macroscopical mineral matter, dietary fiber, can improve immunity,
With anti-inflammatory and pre- aseptic effect.
In the present invention, epiphysin is a kind of amine bormones produced by the pineal body of mammal and the mankind, by right
The adjusting of internal system and work, be a kind of endogenous material, for body be not foreign matter, have its own in vivo
Metabolic pathway, will not cause medicine and its metabolin to accumulate in vivo, and biological half-life is short, and toxicity is minimum.Effect：Can antagonism by
The irritability immunosuppressive effect that mental element (acute anxiety) is induced.Improve the killing activity of macrophage and luring for IL-1
Unboiled water is put down.IL-2 is cooperateed with to improve peripheral blood lymphocytes and eosinophil quantity, enhancing splenocyte NK and LAK activity, promotees
Into inducing for IL-2.
In the present invention, microalgae is a kind of, full of nutrition, photosynthetic availability high autotrophy widely distributed in land, ocean
Plant, belongs to low water plant, average only about 5 microns of each microalgae.Microalgae species is various, typically refers to green containing leaf
Plain A can simultaneously carry out the general name of photosynthetic microorganism.Microalgae includes cyanobacteria, green alga, chrysophyceae and red algae.
In the present invention, compound probiotic is a variety of active microorganism beneficial to host, is colonized in host intestine, reproduction
In system, definite health efficacy can be produced, so as to improve host's microecological balance, plays the active beneficial microbe of beneficial effect
General name, including clostridium butyricum, lactic acid bacteria, Bifidobacterium, lactobacillus acidophilus, actinomyces, saccharomycete etc..
Animal provided by the invention is mainly included with the prevention mechanism of respiratory tract protective agents：1. by strengthening macrophage
And the phagocytic activity of neutrophil leucocyte, improve its chemotaxis；2. activating natural killer cells, promote leaching caused by mitogen
Bar cell Proliferation, makes the helper T lymphocyte (CD4+) of immunologic hypofunction be raised with the ratio of suppressor T lymphocyte (CD8+), extensive
It is multiple normal；3. by stimulating interleukin-a and r-interferon to promote cell immune response.
Animal provided by the invention passes through Pidotimod, Moringa, epiphysin, microalgae and compound benefit with respiratory tract protective agents
Raw bacterium coordinated, fragrant odour, phagostimulating effect, palatability are good, can substantially mitigate animal respiratory disease symptom, improve animal
Immunity of organisms, shortens treatment cycle, and positive effect can be obtained by taking in one week, to the effective percentage reachable more than 96% of dog.
Meanwhile animal provided by the invention also has improvement body environment with respiratory tract protective agents, organ health and anti-aging are safeguarded
Effect.
In the preferred embodiment of the present invention, Moringa is Moringa extract.
Moringa extract can be selected from from Moringa positions such as leaf of Moringa, moringa root, Moringa flower or moringa seeds through existing
The extract obtained after extraction process extraction.
Select Moringa extract preferably to play the effect of Moringa, be fully extracted the active ingredient of Moringa, more
Be conducive to the effect that body absorbs and obtains preferably auxiliary treatment breathing problem.
In the preferred embodiment of the present invention, microalgae is haematococcus pluvialis, more preferably haematococcus pluvialis extraction
Thing.
Haematococcus pluvialis are also known as lake life haematococcus or lake green blood ball algae, are a kind of green algas, belong to volvocales, haematococcus section,
Be suitable for production in nature, it is nontoxic.The content of Determination of Astaxanthin in Haematococcus Pluvialis is 1.5-10%, is counted as natural shrimp
" concentrate " of blue or green element.Compared with the common microalgae such as spirulina, chlorella, haematococcus pluvialis have stronger oxidation resistance.
The extract of haematococcus pluvialis is in gorgeous red, has extremely strong pigment deposition ability, not only it is anti-oxidant, disappear
There is very strong ability in terms of except free radical, and the generation of antibody can be promoted, strengthen the immune function of animal, and can improve
Hair color, improves its ornamental value.
In the preferred embodiment of the present invention, compound probiotic includes clostridium butyricum and bacillus subtilis.
Clostridium butyricum has following effect：1st, intestinal colony balance is adjusted, promotes intestinal beneficial flora propagation；2nd, enhancing is exempted from
Epidemic disease function, 3, production butyric acid reduce gut pH, suppress harmful intestinal tract bacteria growth；4th, metabolite butyric acid promotes gut epithelium tissue
The regeneration and reparation of cell.
The effect of bacillus subtilis：1 production antibacterial substance suppresses harmful bacteria growth；2 consumption enteron aisle free oxygens promote beneficial
Bacterium grows；3 stimulate the growth and development of immune organ, and activation T, bone-marrow-derived lymphocyte, improve immunity；4th, producing enzyme, improves digestibility.
The compound benefit being mainly made of in the of the invention preferred embodiment clostridium butyricum and bacillus subtilis and its
Its raw material mutually cooperates with, and can not only adjust the intestinal colony balance of animal body, suppress harmful bacteria growth, and can stimulate and exempt from
The growth and development of epidemic disease organ, improves the immunity of body, promotes the histiocytic regeneration of gut epithelium and reparation and repairs, improves
Digestibility.
In the preferred embodiment of the present invention, the clump count of compound probiotic is (20-40) × 108cfu/g。
In the typical but non-limiting embodiment of the present invention, the clump count of compound probiotic is 20 × 108、21×
108、22×108、23×108、24×108、25×108、26×108、27×108、28×108、29×108Or 30 × 108cfu/
g。
In the preferred embodiment of the present invention, the present invention provides a kind of animal respiratory tract protective agents, press
The following component of mass fraction meter：2-20 parts of Pidotimod, 5-30 parts of Moringa, 0.1-1 parts of epiphysin, 0.2-3 parts of microalgae and multiple
Close 1-15 parts of probiotics；
In the present invention, the typical but non-limiting mass fraction of Pidotimod as 2,3,4,5,6,7,8,9,10,
11st, 12,13,14,15,16,17,18,19 or 20 parts.
In the present invention, the typical but non-limiting mass fraction of Moringa as 5,6,7,8,9,10,11,12,13,
14th, 15,16,17,18,19,20,21,22,23,24,25,26,27,28,29 or 30 parts.
In the present invention, the typical but non-limiting mass fraction of epiphysin as 0.1,0.15,0.2,0.25,0.3,
0.35th, 0.4,0.45,0.5,0.55,0.6,0.65,0.7,0.75,0.8,0.85,0.9,0.95 or 1 part.
Animal provided by the invention with respiratory tract protective agents by the Pidotimod of extra fine quality number, Moringa, take off it is black
Element, microalgae and compound probiotic coordinated, its palatability is more preferable, and treatment cycle is shorter, can more be effectively improved animal body
Environment, safeguards organ health and anti-aging.
In the preferred embodiment of the present invention, animal further includes multi-vitamins 0.1- with respiratory tract protective agents
10 parts, be preferably 0.1-5 parts.
In the preferred embodiment of the present invention, the typical but non-limiting mass fractions of multi-vitamins is 0.1,
0.2nd, 0.5,0.8,1,1.5,2,2.5,3,3.5,4,4.5,5,6,6.5,7,7.5,8,8.5,9,9.5 or 10 part.
In present invention further optimization embodiment, multi-vitamins include vitamin A, vitamin C, vitamin E,
At least two in vitamin B1, vitamin B2 and D-VB5 calcium, it is highly preferred that multi-vitamins for vitamin A, vitamin C,
Mixture in vitamin E, vitamin B1, vitamin B2 and D-VB5 calcium.
Vitamin A is fat-soluble alcohols material, animal can not only be helped to maintain normal vision function, and can tie up
Hold the health of Epithelial cell and promote the synthesis of immunoglobulin, maintain normal development of skeleton, promote the growth of animal with
Reproduction, prophylactic generation.
Vitamin C is called L-AA, is a kind of water soluble vitamin, and can strengthen body should to the anti-of external environment
The ability of swashing and immunity, strengthen anti-oxidation function, promote bone growth.
Vitamin E is a kind of liposoluble vitamin, its hydrolysate is tocopherol, being capable of anti-lipid peroxidation and formation
Free radical, has very strong oxidation resistance, prevents anaemia, improves lipid-metabolism, anti-aging and anticancer.
Vitamin B1 is also known as thiamine or antineuritic vitamin, to maintaining normal nerve conduction, and heart, digestion
The normal activity of system has the function that important.
Vitamin B2 is called riboflavin, is slightly soluble in water, participates in biological oxidation and energetic supersession in animal body, it is possible to increase machine
To the utilization rate of protein, enhancing development, safeguards the integrality of skin and cell membrane, promotes the absorption of iron body, and has
Antioxidation activity.
D-VB5 calcium is also known as vitamin B5, it is capable of the formation of body promotion cell, maintains normal development and nervous centralis
Infectious disease is resisted in the development of system, help, alleviates Multiple Classes of Antibiotics side effect and toxicity, and can safeguard that hair and blood are good for
Health.
Given birth to by including vitamin A, vitamin C, dimension with addition in respiratory tract protective agents in animal provided by the invention
At least two multi-vitamins being combined, can not only provide dynamic in plain E, vitamin B1, vitamin B2 and D-VB5 calcium
Nutritional ingredient necessary to thing, improve immunity of organisms, and can Green Tea Extract oxidation, promote growth, help digest, improve essence
Refreshing situation, while resisting stress capability can be lifted, promote the regeneration of cell, make the tracheaes such as respiratory tract, oral cavity, stomach and enteron aisle
Mucous membrane it is without prejudice, especially when multi-vitamins for vitamin A, vitamin C, vitamin E, vitamin B1, vitamin B2
During with the mixture of D-VB5 calcium, made animal with the effect of respiratory tract protective agents more preferably.
In the preferred embodiment of the present invention, animal further includes composite trace element with respiratory tract protective agents
0.1-10 parts, be preferably 0.1-5 parts.
In animal provided by the invention with respiratory tract protective agents, the typical but non-limiting matter of composite trace element
It is 0.1,0.2,0.5,0.8,1,1.5,2,2.5,3,3.5,4,4.5,5,6,6.5,7,7.5,8,8.5,9,9.5 or 10 to measure number
Part.
In present invention further optimization embodiment, composite trace element includes at least two in copper, zinc, selenium and manganese
Kind.
One of minor metallic element necessary to copper is animal body, plays particularly significant effect in organism, can be with egg
White matter combines to form cuprein or copper enzyme, participates in the electronics transfer in organism, the conveying of oxygen and the biological oxidation of substrate are also
Original reaction, while the absorption of internal iron can also be adjusted.
Zinc has important physiological action, it can participate in the composition of many metalloenzyme in animal body, promotes animal body
Growth and development and regeneration, and normal development to brain and the stabilization of cell membrane play an important role, and protect the health of skin,
Improve the immune function of animal body.
Selenium is a kind of important trace element, it not only has anti-oxidation function, but also can effectively improve exempting from for body
Epidemic disease is horizontal, promotes basic metabolism, reduces the toxicity of trace element.
Manganese is the composition of a variety of enzymes in animal body, is removing superoxides, enhancing body's immunity etc.
Produce important function.
Animal provided by the invention is with respiratory tract protective agents by adding include in copper, zinc, selenium and manganese at least two
Composite trace element, using the teaching of the invention it is possible to provide superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) synthesis institute
The raw material needed, ensures two kinds of enzymatic synthesis abundances, improves immunity of organisms.When the composite trace element of addition is copper, zinc, selenium and manganese
Mixture when, made animal can more effectively improve animal body immunity with respiratory tract protective agents.
In the preferred embodiment of the present invention, animal further includes activated oligosaccharide 2-10 with respiratory tract protective agents
Part, it is preferably 3-7 parts.
In the preferred embodiment of the present invention, animal with respiratory tract protective agents, activated oligosaccharide it is typical but non-
Restricted mass fraction is 2.2,2.5,2.8,3,3.2,3.5,3.8,4,4.2,4.5,4.8,5,5.2,5.5,5.8,6,
6.2nd, 6.5,6.8,7,7.2,7.5,7.8,8,8.2,8.5,8.8,9,9.2,9.5,9.8 or 10 parts.
In present invention further optimization embodiment, activated oligosaccharide includes mannosan and/or oligoisomaltose.
Manna oligosacchride prevents pathogen to be colonized in enteron aisle, and activating macrophage, bite neutrophil cell, assists damaged tissues as drenched
Bar histocyte accelerates to recover to produce cytokine (IL-1), promotes to include antibiotic, antimycotic, other medicines including anti-parasitic medicine
Thing is preferably played effectiveness.
Oligoisomaltose can promote Bifidobacterium in enteron aisle to breed, and suppress harmful intestinal tract bacteria and corrupt substance is formed, increase
Add vitamin content, improve immunity of organisms.
Animal provided by the invention includes manna oligosacchride and oligoisomaltose with respiratory tract protective agents by adding
Activated oligosaccharide, can not only assist the reparation of damaged tissues in animal volume, and can suppress the breeding of harmful bacteria in enteron aisle,
Promote the performance of animal respiratory tract protective agents drug effect, improve immunity of organisms.
In the preferred embodiment of the present invention, animal further includes 15-50 parts of auxiliary material with respiratory tract protective agents, excellent
Elect 20-40 parts as.
In the preferred embodiment of the present invention, animal with respiratory tract protective agents, auxiliary material it is typical but unrestricted
Property mass fraction as 15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,
35th, 36,37,38,39,40,41,42,43,44,45,46,47,48,49 or 50 parts.
Auxiliary material is added during making, medicine can be fabricated to different dosage forms, increases the consumption and palatability of medicine.
In present invention further optimization embodiment, auxiliary material includes adhesive, disintegrant, lubricant, flavouring agent, breast
At least one of agent, suspending agent, oil phase substrate, aqueous phase substrate, solvent, flavouring agent and diluent；
By adding different types of auxiliary material, the medicine of different dosage forms and flavor is made, easy to various animals
It is edible.
In the preferred embodiment of the present invention, lubricant is selected from silica, magnesium stearate, odium stearate or cunning
At least one of mountain flour.
In the preferred embodiment of the present invention, flavouring agent is at least one in chicken liver meal, pork liver powder or powdered beef
Kind.
By selecting at least one of chicken liver meal, pork liver powder or powdered beef to be used as flavouring agent, to improve the palatability of medicine
And attractant.
In the preferred embodiment of the present invention, disintegrant is selected from sodium carboxymethyl starch, sodium carboxymethylcellulose, micro-
At least one of crystalline cellulose or starch.
By adding disintegrant in medicine, to accelerate the dissolving of medicine in animal body, absorb, shorten dynamic beneficial to animal
The treatment cycle of thing.
In the preferred embodiment of the present invention, diluent in lactose, glucose or mannitol at least one
Kind.
By adding diluent in medicine, to strengthen the palatability of medicine and attractant.
In the preferred embodiment of the present invention, emulsifying agent be selected from lauryl sodium sulfate (SDS), stearate,
Oleate, spans (fatty acid sorbitan class), Tweens (poly yamanashi esters), poloxamer (Pluronic F68), sucrose
Stearate, Brij, sell at least one of pool；
By adding emulsifying agent in medicine, to strengthen the uniformity of each component mixing.
In the preferred embodiment of the present invention, the suspending agent is selected from methylcellulose (MC), carboxymethyl cellulose
Plain sodium (CMC-Na), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), I
Primary glue, at least one of tragacanth, sodium alginate.
In the preferred embodiment of the present invention, oil phase substrate in vegetable oil, atoleine, glycerine at least
It is a kind of.
In a kind of excellent embodiment of the present invention, the one kind of aqueous phase substrate in water or ethanol solution.
In the preferred embodiment of the present invention, the one kind of solvent in water, ethanol, propane diols.
In a kind of preferred embodiment of the present invention, auxiliary material includes following component according to the mass fraction：Adhesive 1-8
Part, 8-20 parts of disintegrant, 1-5 parts of lubricant, 2-10 parts of flavouring agent, 2-20 parts of diluent；Preferably, auxiliary material includes pressing mass parts
Several doses of following component：2-5 parts of adhesive, 10-15 parts of disintegrant, 1-3 parts of lubricant, 3-8 parts of flavouring agent and diluent 5-15
Part.
In the preferred embodiment of the present invention, in auxiliary material the typical but non-limiting mass fraction of adhesive for 1,
1.5th, 2,2.5,3,3.5,4,4.5,5,5.5,6,6.5,7,7.5 or 8 parts；The typical but non-limiting mass fraction of disintegrant
Such as it is 8,9,10,11,12,13,14,15,16,17,18,19 or 20 parts；The typical but non-limiting mass fraction of flavouring agent
Such as it is 2,2.5,3,3.5,4,4.5,5,5.5,6,6.5,7,7.5,8,8.5,9,9.5 or 10 parts；The typical but non-limit of lubricant
The mass fraction of property processed is 1,1.5,2,2.5,3,3.5,4,4.5 or 5 part；The typical but non-limiting mass fraction of diluent
Such as it is 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19 or 20 parts.
In the still more preferably embodiment of the present invention, adhesive is selected from maltodextrin, sodium alginate, polyethylene pyrrole
At least one of pyrrolidone.
In the preferred embodiment of the present invention, by adding adhesive with respiratory tract protective agents in animal, with
Increase the adhesive between different material, easy to which prepared by different material the forms such as piece agent.
In a kind of preferred embodiment of the present invention, animal is tablet, particle with the formulation of respiratory tract protective agents
Agent, paste, parenteral solution, patch, suspension or pulvis；
Preferably, animal is tablet with the formulation of respiratory tract protective agents.
It is convenient to make piece agent animal edible, manufacturing process is simple, is easy to animal and is directly absorbed in body.
According to the second aspect of the invention, the present invention provides the preparation side of above-mentioned animal respiratory tract protective agents
Method, includes the following steps：
By Pidotimod, Moringa, epiphysin, microalgae, optionally compound probiotic, multi-vitamins, optionally compound micro-
Secondary element, optionally activated oligosaccharide and optionally auxiliary material is uniformly mixed, that is, be made animal respiratory tract protective agents.
Animal provided by the invention is simple with the preparation method technique of respiratory tract protective agents, easy to operate, can save
Substantial amounts of manpower and materials, can be suitable for industrialized production.
Animal provided by the invention can be prepared into a variety of formulations with respiratory tract protective agents, such as tablet, granule, paste
Agent, parenteral solution, patch, suspension or pulvis etc..
In the preferred embodiment of the present invention, tablet form animal is included with the preparation method of respiratory tract protective agents
Following steps：
By Pidotimod, Moringa, epiphysin, microalgae, optionally compound probiotic, multi-vitamins, optionally compound micro-
Secondary element, optionally activated oligosaccharide and optionally auxiliary material after mixing, add starch slurry softwood, through pelletizing, dry, obtain
Dry particl, after dry particl tabletting, that is, is made tablet form animal respiratory tract protective agents.
The tablet form animal with the preparation methods of respiratory tract protective agents by raw material through softwood processed, granulation, drying, tabletting,
Tablet is obtained, preparation method is simple, easily operated, does not destroy drug ingedient, and it is easy to use to be made tablet, is easy to absorb.
In a kind of preferred embodiment of the present invention, the mass percentage of starch is 5~15% in starch slurry, example
Such as 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15%.
In a kind of preferred embodiment of the present invention, starch slurry accounts for the quality percentage of animal respiratory tract protective agents
Than for 10~15%, such as 10%, 11%, 12%, 13%, 14% or 15%.
In the preferred embodiment of the present invention, the piece weight of tablet is 0.55-0.65g, such as 0.55,0.56,0.57,
0.58th, 0.59,0.6,0.61,0.62,0.63,0.64 or 0.65g.
In the preferred embodiment of the present invention, tableting pressure 5-7kg, such as 5.1,5.2,5.3,5.4,5.5,
5.6th, 5.7,5.8,5.9,6,6.1,6.2,6.3,6.4,6.5,6.6,6.7,6.8,6.9 or 7kg.
The animal respiratory tract protective agents piece of suitable size can be obtained by control sheet weight and hardness (tableting pressure)
Agent.
In order to further appreciate that the present invention, effect of the present invention is done further in detail with reference to specific embodiment and comparative example
Thin explanation.Each raw material of the present invention can pass through commercially available acquisition.
Embodiment 1
A kind of animal respiratory tract protective agents, are made of following component according to the mass fraction：2 parts of Pidotimod, it is peppery
50 parts of wooden 30 parts of extract, 0.1 part of epiphysin, 3 parts of haematococcus pluvialis, 1 part of compound probiotic and auxiliary material.Wherein, it is compound prebiotic
Bacterium is made of clostridium butyricum and bacillus subtilis, and clump count is 30 × 108cfu/g；Auxiliary material is by 7 parts of sodium alginate, carboxylic first
22 parts of 20 parts of base sodium starch, 3 parts of talcum powder, 8 parts of chicken liver meal and lactose compositions.
Embodiment 2
A kind of animal respiratory tract protective agents, are made of following component according to the mass fraction：20 parts of Pidotimod, it is peppery
Wooden 5 parts of extract, 1 part of epiphysin, 0.2 part of haematococcus pluvialis, 30 parts of 15 parts of compound probiotic, 10 parts of activated oligosaccharide and auxiliary material.
Wherein, compound probiotic is made of clostridium butyricum and bacillus subtilis, and clump count is 20 × 108cfu/g；Activated oligosaccharide is
Mannosan；Auxiliary material is by 5 parts of maltodextrin, 13 parts of sodium carboxymethylcellulose, 2 parts of odium stearate, 3 parts of pork liver powder and glucose 7
Part composition.
Embodiment 3
A kind of animal respiratory tract protective agents, are made of following component according to the mass fraction：5 parts of Pidotimod, it is peppery
Wooden 25 parts of extract, 0.2 part of epiphysin, 0.5 part of haematococcus pluvialis, 12 parts of compound probiotic, 2 parts of activated oligosaccharide and auxiliary material 40
Part.Wherein, compound probiotic is made of clostridium butyricum and bacillus subtilis, and clump count is 22 × 108cfu/g；It is active few
Sugar is oligoisomaltose；Auxiliary material is by 5 parts of polyvinylpyrrolidone part, 10 parts of sodium carboxymethylcellulose, 3 parts of odium stearate, ox
12 parts of compositions of 10 parts of digested tankage and mannitol.
Embodiment 4
A kind of animal respiratory tract protective agents, are made of following component according to the mass fraction：18 parts of Pidotimod, it is peppery
Wooden 8 parts of extract, 0.5 part of epiphysin, 2 parts of haematococcus pluvialis, 40 parts of 3 parts of compound probiotic, 7 parts of activated oligosaccharide and auxiliary material.Its
In, compound probiotic is made of clostridium butyricum and bacillus subtilis, and clump count is 28 × 108cfu/g；Activated oligosaccharide is by sweet
Reveal glycan and oligoisomaltose composition, and both mass ratioes are 1:1；Auxiliary material is by 5 parts of polyvinylpyrrolidone part, carboxymethyl
9 parts of 15 parts of sodium cellulosate, 3 parts of odium stearate, 8 parts of powdered beef and mannitol compositions.
Embodiment 5
A kind of animal respiratory tract protective agents, are made of following component according to the mass fraction：8 parts of Pidotimod, it is peppery
Wooden 20 parts of extract, 0.4 part of epiphysin, 1 part of haematococcus pluvialis, 5 parts of compound probiotic, 7 parts of activated oligosaccharide, multi-vitamins
0.1 part and 35 parts of auxiliary material.Wherein, compound probiotic is made of clostridium butyricum and bacillus subtilis, and clump count for 24 ×
108cfu/g；Activated oligosaccharide is made of mannosan and oligoisomaltose, and both mass ratioes are 1:1；Multi-vitamins
It is made of vitamin A, vitamin C and vitamin E, and the mass ratio of three is 1:1:1；Auxiliary material is by 3 parts of sodium alginate, carboxymethyl
13 parts of 12 parts of sodium starch, 2 parts of talcum powder, 5 parts of chicken liver meal and lactose compositions.
Embodiment 6
A kind of animal respiratory tract protective agents, are made of following component according to the mass fraction：16 parts of Pidotimod, it is peppery
Wooden 10 parts of extract, 0.4 part of epiphysin, 1.2 parts of haematococcus pluvialis, 8 parts of compound probiotic, 5 parts of activated oligosaccharide, multi-vitamins
10 parts and 35 parts of auxiliary material.Compound probiotic is made of clostridium butyricum and bacillus subtilis, and clump count is 24 × 108cfu/g；
Activated oligosaccharide is made of mannosan and oligoisomaltose, and both mass ratioes are 1:1；Multi-vitamins by vitamin A,
Vitamin C, vitamin E, vitamin B1, vitamin B2 and D-VB5 calcium composition, and five mass ratio is 1:1:1:1:1；It is auxiliary
Material is made of 6 parts of 5 parts of sodium alginate, 15 parts of sodium carboxymethyl starch, 3 parts of talcum powder, 6 parts of chicken liver meal and lactose.
Embodiment 7
A kind of animal respiratory tract protective agents, are made of following component according to the mass fraction：16 parts of Pidotimod, it is peppery
Wooden 18 parts of extract, 0.4 part of epiphysin, 1.2 parts of haematococcus pluvialis, 8 parts of compound probiotic, 5 parts of activated oligosaccharide, multi-vitamins
25 parts of 5 parts, 0.1 part of composite trace element and auxiliary material.Compound probiotic is made of clostridium butyricum and bacillus subtilis, and bacterium colony
Number is 24 × 108cfu/g；Activated oligosaccharide is made of mannosan and oligoisomaltose, and both mass ratioes are 1:1；It is multiple
Vitamin is closed to be made of vitamin A, vitamin C, vitamin E, vitamin B1, vitamin B2 and D-VB5 calcium, and five matter
Amount is than being 1:1:1:1:1；Trace element is made of zinc and selenium, and both mass ratioes are 1：1, auxiliary material is by 5 parts of sodium alginate, carboxylic
3 parts of 10 parts of methyl starch sodium, 3 parts of talcum powder, 4 parts of chicken liver meal and lactose compositions.
Embodiment 8
A kind of animal respiratory tract protective agents, are made of following component according to the mass fraction：12 parts of Pidotimod, it is peppery
Wooden 15 parts of extract, 0.4 part of epiphysin, 1.3 parts of haematococcus pluvialis, 7 parts of compound probiotic, 5 parts of activated oligosaccharide, multi-vitamins
30 parts of 5 parts, 5 parts of composite trace element and auxiliary material.Compound probiotic is made of clostridium butyricum and bacillus subtilis, and clump count
For 24 × 108cfu/g；Activated oligosaccharide is made of mannosan and oligoisomaltose, and both mass ratioes are 1:1；It is compound
Vitamin is made of vitamin A, vitamin C, vitamin E, vitamin B1, vitamin B2 and D-VB5 calcium, and five quality
Than for 1:1:1:1:1；Trace element is made of copper, zinc, manganese and selenium, and four mass ratio is 1:2:2:1, auxiliary material is by alginic acid
5 parts of 3 parts of sodium, 15 parts of sodium carboxymethyl starch, 2 parts of talcum powder, 5 parts of chicken liver meal and lactose compositions.
Embodiment 9-16
A kind of preparation method of animal respiratory tract protective agents, the component that embodiment 1-7 is respectively adopted are prepared, bag
Include following steps：
The component of embodiment 1-7 is crossed into 60 mesh sieves, after mixing, 10% starch slurry softwood of mass concentration is added, forms sediment
Slurry accounts for the 10% of medicine total amount；The softwood made is put into wet granular processed in oscillating granulator, sieve mesh number is 20 mesh；Will
The wet granular prepared, which is uniformly laid on, to be placed in stainless steel pallet, is no more than 2cm per disc thickness, is put in heated-air circulation oven, if
Determine 50 DEG C of drying temperature, material is dried, when every 100kg wet feed drying times are about 4-5 small, one is stirred when 1 is small
Secondary, moisture is controlled in 3.0-5.0%；The particle of drying is crossed into 30 mesh, is allowed to be dispersed into uniform dry particl；Tabletting, piece are controlled again
System is in 0.6 ± 0.02g, hardness：5-7kg pressure.
Comparative example 1
A kind of animal respiratory tract protective agents, this comparative example as different from Example 8, in medicine without more than not
Moral.
Comparative example 2
A kind of animal respiratory tract protective agents, this comparative example as different from Example 8, are extracted in medicine without Moringa
Thing.
Comparative example 3
A kind of animal respiratory tract protective agents, this comparative example as different from Example 8, are free of epiphysin in medicine.
Comparative example 4
A kind of animal respiratory tract protective agents, this comparative example are as different from Example 8, red without rain life in medicine
Algae.
Comparative example 5
A kind of animal respiratory tract protective agents, this comparative example are free of compound prebiotic as different from Example 8, in medicine
Bacterium.
Comparative example 6
A kind of animal respiratory tract protective agents, the difference of this comparative example and embodiment 8 are：1 part of Pidotimod,
34 parts of Moringa extract, 0.5 part of epiphysin, 0.1 part of haematococcus pluvialis, 0.1 part of compound probiotic, other raw materials and auxiliary material with
Embodiment 8 is identical.
Comparative example 7
A kind of animal respiratory tract protective agents, the difference of this comparative example and embodiment 8 are：Pidotimod 28
Part, 3 parts of Moringa extract, 2 parts of epiphysin, 5 parts of haematococcus pluvialis, 0.1 part of compound probiotic, other raw materials and auxiliary material with reality
It is identical to apply example 8.
Comparative example 8-14
A kind of preparation method of animal respiratory tract protective agents, the component that comparative example 1-7 is respectively adopted are prepared, bag
Include following steps：
The component of comparative example 1-7 is crossed into 60 mesh sieves, after mixing, 10% starch slurry softwood of mass concentration is added, forms sediment
Slurry accounts for the 10% of medicine total amount；The softwood made is put into wet granular processed in oscillating granulator, sieve mesh number is 20 mesh；Will
The wet granular prepared, which is uniformly laid on, to be placed in stainless steel pallet, is no more than 2cm per disc thickness, is put in heated-air circulation oven, if
Determine 50 DEG C of drying temperature, material is dried, when every 100kg wet feed drying times are about 4-5 small, one is stirred when 1 is small
Secondary, moisture is controlled in 3.0-5.0%；The particle of drying is crossed into 30 mesh, is allowed to be dispersed into uniform dry particl；Tabletting, piece are controlled again
System is in 0.6 ± 0.02g, hardness：5-7kg pressure.
Test example 1
By the animal that embodiment 1-8 and comparative example 1-7 are obtained with respiratory tract protective agents to breathing problem
Canine is tested, and evaluates its adjuvant treatment effect to breathing problem, and specific experiment process is as follows：
(1) test material
" the match level number R-King " systems that basic dog grain is provided by Lei meter Gao animal nutritious healths Science and Technology Ltd. of Foshan City
Arrange into dog grain；Lincomycin Hydrochloride piece, experiment tablet are provided by east Ao Long pharmaceutical Co. Ltds.
(2) experimental animal and packet
The dog 450 for the clinical natural occurrence respiratory bacterial infections made a definite diagnosis, year are provided by Lei meter Gao pet clinics
Age is unlimited, and male or female, weight is unlimited, selected to test dog first attack and without antibiosis extract for treating；Cough, asthma, body temperature liter
It is high；Blood testing total white blood cells rise more than 100%；Conducting lung X-ray examination piece checks increased bronchovascular shadows person.All experimental dogs have connect
Kind dog quadruple vaccine.
Experimental dog is randomly divided into 16 groups, every group 30：
Blank control group 2 times a day, is used in conjunction 7 days according to 25mg/kg bodyweight p Lincomycin Hydrochloride pieces.
One~test group of test group nine is respectively according to 25mg/kg bodyweight p Lincomycin Hydrochloride piece+0.06g/kg weight
The animal respiratory tract protective agents that oral embodiment 7-12 and comparative example 4-6 is obtained, 2 times a day, are used in conjunction 7 days.
(3) detection project is tested
Routine inspection：Symptom before and after record experiment dog medication：The number of cough per minute, Respiration Rate, body temperature value.
Laboratory examination：On the day of before experiment starts medication, the 7th day after medication, every dog blood sample is gathered, carries out dog blood
Routine inspection；And lung X-ray optical test analysis result was carried out with the 7th day on the day of medication.
(4) curative effect judges (the 7th day detected value)
Recovery from illness：Normal (the normal body temperature range of body temperature：Puppy：38.5℃-38.8℃；Toy dog：38℃-38.5℃；Adult
Dog：37.5℃-38.5℃；Large-scale dog：37 DEG C -38.5 DEG C), feeding and drinking-water are normal, and no cough symptom, X-ray film lung marking is not
Thickening；Normal (Healthy Dogs total white blood cells scope 6.0-17.00 × 10 of blood leucocyte Index for examination9/L)；
It is effective：Body temperature is normal, and feeding and drinking-water are normal, no cough symptom, X-ray film increased bronchovascular shadows unobvious；Blood is white
Cytoscopy index is normal (be not higher than Upper Limit of Normal Value 10%)；
Effectively：Temperature decline searches for food and drinks water normal to close to normal value (less than 0.5 degree)；Accidental cough symptom
(being no more than 10 times daily), thickening that X-ray film lung marking is slight；Blood leucocyte sum is normal (not higher than normal value
20%)；
It is invalid：Body temperature is normal or more than 0.5 degree higher, and feeding and amount of drinking water are less than normal 70%；Cough
Shape is obvious (daily more than 30 times, rale), X-ray film increased bronchovascular shadows；Blood routine examination total white blood cells rise 100% with
On；
Deteriorate：Body temperature raises (more than 39.5 DEG C), and feeding and drinking-water reduce more than 50%；Cough symptom aggravates, and auscultation is in
Obvious dryness or moist sound of vomiting sound, X-ray film increased bronchovascular shadows；Blood routine examination total white blood cells rise more than 150%.
Remarks：X-ray film criterion is：(1) normally, lung marking is unchanged, and hilar lymph node is normal；(2) mild inflammation,
Hyperplasia that lung marking is slight, hilar lymph node slightly increase；(3) seriously, lung marking hyperplasia is obvious, and hilar lymph node increase (exceedes
More than the 100% of normal bulk area).
(5) result of the test
As shown in table 1.
Table 1 is to breathing problem adjuvant treatment effect
As can be seen from Table 1, animal provided by the invention can substantially mitigate exhaling for diseased canine with respiratory tract protective agents
Road symptom is inhaled, arranges in pairs or groups and uses with conventional antibiotic, the treatment cycle to breathing problem can be obviously shortened, seven days efficient reachable
More than 96%, control group oral hydrochloride lincomycin piece is treated, and seven days efficient only 83.3%, causes treatment time
It is long.Further it can be seen that the animal that test group embodiment 1-8 is provided can further enhance treatment with respiratory tract protective agents
Effect and shortening treatment cycle, cure rate, obvious effective rate are further lifted within seven days.
Test group two-nine is more preferable to the adjuvant treatment effect of respiratory tract compared with test group ten-ten three, it can be seen that, this
The animal provided is invented with respiratory tract protective agents by the collaboration of Pidotimod, Moringa, epiphysin, microalgae and compound probiotic to be matched somebody with somebody
Close, it is possible to increase therapeutic effect, shortens treatment cycle, lifts seven days cure rates and obvious effective rate.
Test group two-nine is more preferable to the adjuvant treatment effect of respiratory tract compared with test group ten four-ten five, it can be seen that,
The ratio of raw material plays an important role the effect of medicine, and suitable ratio can obtain more preferable therapeutic effect and treatment cycle.
Test example 2
The blood that control group in test example 1 and test group one are tested the previous day and tested one day after in dog body is examined
Survey, the results are shown in Table 2.
Influence (10 of the table 2 to physiochemical indice9/L)
As can be seen from Table 2, control group and test group experiment the previous day animal body in leukocyte count, lymphocyte number and
Neutrophil leucocyte number is in fairly horizontal, tests the leukocyte count in test group animal body, lymphocyte number and neutrality one day after
Granulocyte number declines obvious compared with control group, it is seen that test group medicine plays the effect of auxiliary treatment inflammation disease well.
Test example 3
The animal that embodiment 8 provides is subjected to clinical practice with respiratory tract protective agents, typical hospitalize case is for example
Shown in table 3.
3 hospitalize case of table
As can be seen from Table 3, it is obvious to curative effect after the respiratory tract protective agents of the animal practical application present invention, disease in seven days
Shape can be alleviated or disappear, and be capable of the treatment cycle of breathing problem, and animal recovery effects are good.
Although being illustrated and the invention has been described with specific embodiment, but will be appreciated that without departing substantially from the present invention's
Many other change and modification can be made in the case of spirit and scope.It is, therefore, intended that wrap in the following claims
Include all such changes and modifications belonged in the scope of the invention.
Claims (10)
1. a kind of animal respiratory tract protective agents, it is characterised in that including Pidotimod, Moringa, epiphysin, microalgae and compound
Probiotics；
Preferably, the Moringa is Moringa extract；
Preferably, the microalgae is haematococcus pluvialis；
Preferably, the compound probiotic includes clostridium butyricum and bacillus subtilis.
2. animal according to claim 1 respiratory tract protective agents, it is characterised in that including according to the mass fraction as
Lower component：1-15 parts of 2-20 parts of Pidotimod, 5-30 parts of Moringa, 0.1-1 parts of epiphysin, 0.2-3 parts of microalgae and compound probiotic.
3. animal according to claim 1 respiratory tract protective agents, it is characterised in that including according to the mass fraction as
Lower component：5-18 parts of Pidotimod, 8-25 parts of Moringa, 0.2-0.6 parts of epiphysin, 0.5-2 parts of microalgae and compound probiotic 3-12
Part；
Preferably, Pidotimod 8-16 parts, 10-20 parts of Moringa, 0.2-0.6 parts of epiphysin, 0.5-2 parts of microalgae and compound probiotic
3-12 parts.
4. animal according to claim 1 respiratory tract protective agents, it is characterised in that further include multi-vitamins 0.1-
10 parts, be preferably 0.1-5 parts；
Preferably, it is general to include vitamin A, vitamin C, vitamin E, vitamin B1, vitamin B2 and D- for the multi-vitamins
At least two in sour calcium.
5. animal according to claim 1 respiratory tract protective agents, it is characterised in that further include composite trace element
0.1-10 parts, be preferably 0.1-5 parts；
Preferably, the composite trace element includes at least two in copper, zinc, selenium and manganese.
6. animal according to claim 1 respiratory tract protective agents, it is characterised in that further include activated oligosaccharide 2-10
Part, it is preferably 3-7 parts；
Preferably, the activated oligosaccharide includes mannosan and/or oligoisomaltose.
7. animal according to claim 1 respiratory tract protective agents, it is characterised in that 15-50 parts of auxiliary material is further included, it is excellent
Elect 20-40 parts as；
Preferably, the auxiliary material includes adhesive, disintegrant, lubricant, flavouring agent, emulsifying agent, suspending agent, oil phase substrate, water
At least one of phase matrix, solvent, flavouring agent and diluent；
Preferably, described adhesive is selected from least one of maltodextrin, sodium alginate, polyvinylpyrrolidone；
Preferably, the disintegrant in sodium carboxymethyl starch, sodium carboxymethylcellulose, microcrystalline cellulose or starch at least
It is a kind of；
Preferably, the lubricant is selected from least one of silica, magnesium stearate, odium stearate or talcum powder；
Preferably, the emulsifying agent is selected from lauryl sodium sulfate, stearate, oleate, spans, Tweens, Bo Luosha
Nurse, sucrose stearate, Brij, sell at least one of pool；
Preferably, it is fine to be selected from methylcellulose, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methyl for the suspending agent
Tie up element, hydroxyethyl cellulose, Arabic gum, at least one of tragacanth, sodium alginate；
Preferably, the oil phase substrate is selected from least one of vegetable oil, atoleine, glycerine；
Preferably, the one kind of the aqueous phase substrate in water or ethanol solution；
Preferably, the one kind of the solvent in water, ethanol, propane diols；
Preferably, the flavouring agent is selected from least one of plants essential oil, chicken liver meal, pork liver powder or powdered beef；
Preferably, the diluent is selected from least one of lactose, glucose or mannitol.
8. according to claim 1-7 any one of them animal respiratory tract protective agents, it is characterised in that the animal is with exhaling
The formulation for inhaling road protective agents is tablet, granule, paste, oral liquid, parenteral solution, cream, patch, suspension or pulvis；
Preferably, the animal is tablet with the formulation of respiratory tract protective agents.
9. according to the preparation method of claim 1-8 any one of them animal respiratory tract protective agents, it is characterised in that bag
Include following steps：
By Pidotimod, Moringa, epiphysin, microalgae, optionally compound probiotic, multi-vitamins, optionally compound micro member
Element, optionally activated oligosaccharide and optionally auxiliary material is uniformly mixed, that is, be made animal respiratory tract protective agents.
10. the animal according to claim 9 preparation method of respiratory tract protective agents, it is characterised in that more than general not
Moral, Moringa, epiphysin, microalgae, optionally compound probiotic, multi-vitamins, optionally composite trace element, optionally activity
Oligosaccharides and optionally auxiliary material after mixing, add starch slurry softwood, through pelletizing, dry, obtain dry particl, dry particl tabletting
Afterwards, that is, tablet form animal respiratory tract protective agents are made；
Preferably, the mass percentage of starch is 5~15% in starch slurry；
Preferably, the mass percent that starch slurry accounts for animal respiratory tract protective agents is 10~15%；
Preferably, the piece weight of tablet is 0.55-0.65g；
Preferably, tableting pressure 5-7kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711499195.9A CN107952062A (en) | 2017-12-29 | 2017-12-29 | Animal respiratory tract protective agents and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711499195.9A CN107952062A (en) | 2017-12-29 | 2017-12-29 | Animal respiratory tract protective agents and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107952062A true CN107952062A (en) | 2018-04-24 |
Family
ID=61956083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711499195.9A Pending CN107952062A (en) | 2017-12-29 | 2017-12-29 | Animal respiratory tract protective agents and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107952062A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102651973A (en) * | 2009-12-18 | 2012-08-29 | 希尔氏宠物营养品公司 | Pet food compositions including probiotics and methods of manufacture and use thereof |
| CN104474526A (en) * | 2014-11-21 | 2015-04-01 | 成都乾坤动物药业有限公司 | Pharmaceutical composition for treating or/and preventing pet viral diseases and preparation method thereof |
| CN104757297A (en) * | 2015-03-20 | 2015-07-08 | 湖州品创孵化器有限公司 | Health care dog food capable of increasing immunity |
| CN107173561A (en) * | 2017-06-19 | 2017-09-19 | 佛山市南海东方澳龙制药有限公司 | Ruminant nutrition enhancer and preparation method thereof |
-
2017
- 2017-12-29 CN CN201711499195.9A patent/CN107952062A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102651973A (en) * | 2009-12-18 | 2012-08-29 | 希尔氏宠物营养品公司 | Pet food compositions including probiotics and methods of manufacture and use thereof |
| CN104474526A (en) * | 2014-11-21 | 2015-04-01 | 成都乾坤动物药业有限公司 | Pharmaceutical composition for treating or/and preventing pet viral diseases and preparation method thereof |
| CN104757297A (en) * | 2015-03-20 | 2015-07-08 | 湖州品创孵化器有限公司 | Health care dog food capable of increasing immunity |
| CN107173561A (en) * | 2017-06-19 | 2017-09-19 | 佛山市南海东方澳龙制药有限公司 | Ruminant nutrition enhancer and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 《中国化学工业年鉴》编辑部: "《中国化学工业年鉴》", 31 December 2004, 中国化工信息中心 * |
| 占今舜等: "浅谈褪黑素在动物生产中的应用", 《饲料博览》 * |
| 王培磊: "《海洋微藻研究》", 31 January 2015, 山东人民出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaoud | Effect of Spirulina platensis as a dietary supplement on broiler performance in comparison with prebiotics | |
| JP5517215B2 (en) | Fermentation and culture method, plant fermented extract, plant fermented extract powder and blended plant fermented extract | |
| JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN112716982B (en) | Lactic acid bacteria-containing composition and use thereof | |
| CN106420847B (en) | Composition for assisting in protecting gastric mucosa and/or relieving gastrectasia and microecological preparation thereof | |
| CN101384700A (en) | Novel lactobacillus strains and their use against helicobacter pylori | |
| CN1119154C (en) | Live triple bifidobacteria preparation and preparing method thereof | |
| CN107927794A (en) | A kind of probiotics functional food composition and preparation method thereof | |
| CN102028110A (en) | Probiotic-astragalus polysaccharide composition for feeding commercial chicken | |
| CN104997816B (en) | Improve the pine pollen composition and application thereof of gastrointestinal function | |
| WO2010001509A1 (en) | Novel lactic acid bacterium having high immunoglobulin-a-inducing ability | |
| CN115211502A (en) | Compound tablet for regulating intestinal health, preparation method and application thereof | |
| CN116855413B (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN107752015A (en) | The composite nutrient food that a kind of all-digestive tract improves | |
| CN110193030A (en) | A kind of dog probiotics and preparation method thereof | |
| CN115844019A (en) | Probiotic capable of regulating intestinal tract and application | |
| CN106889615B (en) | Microelement selenium dietary supplement with function of regulating intestinal flora and application thereof | |
| CN109221697A (en) | Weaned piglets probiotic feed and preparation method thereof | |
| CN108853026A (en) | A kind of andrographolide for animals is scattered | |
| CN114470084A (en) | Environment-friendly and efficient composition for preventing and treating white feces of tilapia mossambica as well as preparation method and application thereof | |
| CN107952062A (en) | Animal respiratory tract protective agents and preparation method thereof | |
| CN107929744A (en) | The application in respiratory drugs are prepared of Moringa and pidotimod composition, animal respiratory tract protective agents and preparation method thereof | |
| RU2257408C1 (en) | Curative-prophylactic biopreparation based on dry biomass of bifidum bacteria and lactic acid bacteria, biologically active food supplement based on dry biomass of bifidum bacteria and lactic acid bacteria, dry biomass of bifidum bacteria and lactic acid bacteria and method for its preparing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180424 |
|
| RJ01 | Rejection of invention patent application after publication |